Tongrentang Chinese Medicine Reports Interim Results with Profit Dip to HK$198 Million

Stock News
Aug 28

TONGRENTANGCM (03613) has announced its interim results for the 2026 fiscal period, revealing a 15.6% year-on-year decline in profit attributable to shareholders, which settled at approximately HK$198 million.

Revenue for the period reached about HK$602 million, representing a 21% decrease compared to the previous year, with earnings per share recorded at HK$0.24.

The company noted that its gross margin improved to 63.9% during the period, up from 60.8% in the corresponding period last year, marking a year-on-year increase of 3.1 percentage points. Furthermore, the smaller decline in profit relative to revenue indicates that the company's ongoing efforts in cost control and product mix optimization are delivering tangible results.

During the period, the company maintained a robust capital structure with ample operating cash flow and minimal interest-bearing debt, providing strong financial resilience. Inventory levels continued to decrease, asset allocation became further concentrated on core business operations, and the overall asset structure saw sustained optimization.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10